Volume 56, Pages S41-S45 (November 1999)

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Erythropoietin should be part of congestive heart failure management

Anemia management in chronic kidney disease

Erythropoietin should be part of congestive heart failure management

Volume 56, Pages S95-S98 (November 1999)

Lipopheresis in the nephrotic syndrome

Impact of new dialysis solutions on peritonitis rates

Volume 64, Pages S72-S77 (November 2003)

Zaccaria Ricci, Claudio Ronco, Sergio Picardo Kidney International

Volume 80, Issue 10, Pages (November 2011)

Progression of renal failure and hypertensive nephrosclerosis

George A. Kaysen, Burl R. Don

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Volume 71, Issue 11, Pages (June 2007)

Edmund G. Lowrie Kidney International

Study of Heart and Renal Protection (SHARP)

Volume 73, Pages S5-S17 (April 2008)

Public health in Africa: What is new—The context, the gains, the losses, the renewed public health, and the way forward D.A.N.C.O. Kaseje, Pamela Juma,

Anemia as a risk factor for cardiovascular disease

New insights in uremic toxins

The third World Kidney Day: Looking back and thinking forward

Volume 64, Pages S72-S77 (November 2003)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 63, Pages S38-S42 (February 2003)

Proteinuria and hypertensive nephrosclerosis in African Americans

Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier

Microbiology and outcomes of peritonitis in North America

Volume 74, Issue 8, Pages (October 2008)

Nephrology in Latin America, with special emphasis on Brazil

Methods for guideline development

Future of icodextrin as an osmotic agent in peritoneal dialysis

AGEs in foods: Do they play a role in uremia?

Simvastatin in nephrotic syndrome

Counteracting progression of renal disease: A look into the future

Nephrology Crossword: Glomerulonephritis

Volume 56, Pages S29-S31 (November 1999)

Homocysteine, renal function, and risk of cardiovascular disease

Proteinuria screening for children

Volume 82, Issue 9, Pages (November 2012)

Peritoneal dialysis in Mexico

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Clinical benefits of slowing the progression of renal failure

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Volume 56, Pages S71-S74 (November 1999)

Atherosclerotic nephropathy

Volume 55, Pages S3-S16 (June 1999)

Volume 56, Pages S37-S40 (November 1999)

Cardiovascular risk in chronic kidney disease

Volume 70, Issue 7, Pages (October 2006)

Charles A. Herzog Kidney International

Volume 76, Issue 1, Pages 8-10 (July 2009)

Is complement a target for therapy in renal disease?

Volume 70, Issue 3, Pages (August 2006)

Volume 70, Issue 5, Pages (September 2006)

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 60, Issue 5, Pages (November 2001)

Volume 75, Issue 8, Pages (April 2009)

Volume 55, Pages S41-S46 (June 1999)

Morphology of the heart and arteries in renal failure

Development and differentiation of endothelium

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Presentation transcript:

Volume 56, Pages S41-S45 (November 1999) Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes Dr Rolf D. Frank, Heiko Farber, Ioannis Stefanidis, Regina Lanzmich, Horst P. Kierdorf Kidney International Volume 56, Pages S41-S45 (November 1999) DOI: 10.1046/j.1523-1755.56.s72.3.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Schematic drawing of the in vitro hemofiltration model. Kidney International 1999 56, S41-S45DOI: (10.1046/j.1523-1755.56.s72.3.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Time course of the prefilter recombinant (r)-hirudin levels during in vitro hemofiltration. Starting from the same level at t = 0 min, the r-hirudin level (mean ± sd) declined more rapidly with F50 () compared with Nephral 200 (▪). The differences were statistically significant at time points 5, 10, 15, and 20 minutes (P < 0.05). The control experiments (lines) showed unchanged r-hirudin levels [(□) F50, (♦) Nephral 200]. Kidney International 1999 56, S41-S45DOI: (10.1046/j.1523-1755.56.s72.3.x) Copyright © 1999 International Society of Nephrology Terms and Conditions